Analyst: Focus on Bavarian Nordic's 2022 outlook, orders and costs in upcoming report

On Friday, Bavarian Nordic will present its year-end results for 2021, but Sydbank Analyst Søren Løntoft Hansen will skip straight to the company’s guidance for this year.

Photo: Bavarian Nordic / PR

Increasing research and development costs have stifled some of the expectations for biotech company Bavarian Nordic’s full-year results, which will be released on Friday.

As is custom, Bavarian Nordic’s 2022 guidance will be included in the report, and this section will be of particular interest, says Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs